Catalyst

Slingshot members are tracking this event:

Egalet Announces FDA Acceptance of New Drug Application for ARYMO ER (Morphine Sulfate) Extended-Release Tablets

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EGLT

100%

Additional Information

Additional Relevant Details
The 505(b)(2) regulatory submission is based on pivotal pharmacokinetic studies that demonstrated bioequivalence of ARYMO ER 15 mg, 30 mg and 60 mg to equivalent doses of MS Contin (morphine sulfate controlled-release). In addition, the submission includes a comprehensive battery of Category 1, 2 and 3 abuse-deterrent studies which were all conducted in accordance with the April 2015 U.S. Food and Drug Administration (FDA) Guidance for Industry, Abuse-Deterrent Opioids – Evaluation and Labeling to support abuse-deterrent label claims for ARYMO ER regarding intravenous injection, snorting and oral routes of misuse and abuse.The FDA indicated that they currently plan to hold an advisory committee meeting to discuss the application.
http://egalet.invest...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nda, Arymo Er, Morphine Sulfate, Pain, Opioid Treatment